Board of Directors
CEO, Founder and Director
Dr Sunstrom has been the CEO of NeuClone since it was established in 2007. Dr Sunstrom has over 20 years experience in the biopharmaceutical industry including more than 10 years of executive experience in biopharmaceutical companies. Dr Sunstrom has led teams in product development from bench to the market and founded and led two biotechnology companies based on CHO cell line development. Dr Sunstrom has held previous positions as CSO and Co-Founder of Acyte Biotech Pty Ltd as well as Deputy Director of both the CRC for Biopharmaceutical Research and the Bioengineering Centre at the University of New South Wales.
RUSSELL J. HOWARD
Dr Russell Howard joined NeuClone as Executive Chairman in January 2013. As a Senior executive with 15 years of CEO experience leading technology-based Life Science companies, most notably Maxygen Inc (NASDAQ: MAXY), Dr Howard has led corporate development strategies to generate over 30 products marketed worldwide and raised over $250 million on the U.S. public equity market. Dr Howard is also the inventor of a rapid, inexpensive, human malaria diagnostic test marketed worldwide for 17 years. Dr Howard has a breadth of technical experience in product discovery and development for pharmaceuticals and has published over 140 scientific publications in refereed journals and is an inventor on five issued patents. Russell is also non-executive director of Prima Biomed (ASX: PRD).
DAVID W. ANSTICE
David W. Anstice is a retired senior executive and company director, working globally, and based in Pennsylvania, USA. Today, in addition to being a director of NeuClone, he is a non-executive director of two public companies, CSL Limited (ASX: CSL), based in Melbourne, Australia and Alkermes Plc, based in Dublin, Ireland (NASDAQ: ALKS).
Mr. Anstice retired as a senior executive of Merck & Co., Inc., in September 2008, after a 35 year career. He had reported to Merck’s CEO, in various assignments, including President, The Americas; President, Asia Pacific; and President, Japan, since 1994. Prior to that date he was President of Merck’s European business. Mr. Anstice also served on the Board of Directors, and Executive Committee, of the Biotechnology Industry Organization in Washington, D.C. from 1996 to 2005.
Chief Financial Officer & General Counsel, Executive Director
John Macphillamy is a business consultant and director. He has had over 45 years experience in business in Australia and overseas in both publicly listed and private companies in operations and management. Mr MacPhillamy has recently retired as CFO/ Legal Counsel / Company Secretary from Grant Samuel, an Australian Corporate Advisory firm. Throughout his career, John has been involved in Director and Executive Management, Business Strategy, Risk Management, Corporate Governance, Regulatory Compliance, Finance, Legal, Private Equity and M&A activities. Mr Macphillamy has also been involved in the agricultural technology sector. John holds qualifications in Economics, Law and Management.
Robert Johanson has worked at corporate advisory firm Grant Samuel since 1993 and is responsible for its Melbourne office. Robert has 30 years’ experience in corporate finance and investment banking, including the corporate division of Macquarie Bank, and has been involved in a wide variety of capital markets transactions for leading corporations. Previously he worked as a solicitor, a law lecturer and as a consultant to mining and finance businesses. He is the Chairman of Bendigo and Adelaide Bank Limited. He is Deputy Chancellor at the University of Melbourne and Chairman of the Melbourne University Fund. He is Chairman of the Australia India Institute, a member of the Takeovers Panel and a director of the Robert Salzer Foundation, an arts foundation.
Jean Payette is an Industrial Designer and investor with over 20 years experience in designing and marketing of numerous medical-related products. Jean specialises in the design of laboratory equipment for biopharmaceutical applications using process feature-based design methods and incorporating cost-effective production processes.